Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeong Kim

Internal Medicine Bothell, WA Medical Doctor

NPI 1861591786 CMS profile 175085

11812 N Creek Pkwy N Ste 202, Bothell, WA 98011

Open in the dashboard

General payments

$3,362

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeong Kim of Bothell, WA is reported in the CMS Open Payments database as having received $3,362 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $698 33
2024 General $255 18
2023 General $319 21
2022 General $665 36
2021 General $680 39
2020 General $345 16
2019 General $400 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeong Kim
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jeong Kim were reported at $698. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jeong Kim Internal Medicine median Middle half National median
2019 $400 $159 $48–$570 $163
2020 $345 $119 $33–$402 $114
2021 $680 $135 $37–$521 $132
2022 $665 $141 $42–$496 $149
2023 $319 $149 $45–$519 $160
2024 $255 $154 $47–$537 $164
2025 $698 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orexo US, Inc. $1,230 96 payments
  2. Indivior Inc. $299 10 payments
  3. Alkermes, Inc. $257 14 payments
  4. Braeburn Inc. $231 9 payments
  5. Abbott Laboratories $200 1 payment
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $183 9 payments
  7. Pfizer Inc. $159 6 payments
  8. US WorldMeds, LLC $143 2 payments
  9. Novo Nordisk Inc $119 3 payments
  10. Janssen Pharmaceuticals, Inc $99 5 payments
  11. Other $442 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,357 177 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. Zubsolv $1,010 80 payments
  2. BRIXADI $231 9 payments
  3. VIVITROL $230 13 payments
  4. SUBLOCADE $212 7 payments
  5. AMPLATZER AMULET $200 1 payment
  6. SPIRIVA RESPIMAT $183 9 payments
  7. Lucemyra/Lofexidine $143 2 payments
  8. STIOLTO RESPIMAT $142 7 payments
  9. RYBELSUS $119 3 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $110 4 payments
  11. Other $1,221 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record